139 related articles for article (PubMed ID: 22537224)
1. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
2. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
3. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.
Duan W; Gao L; Zhao W; Leon M; Sadee W; Webb A; Resnick K; Wu X; Ramaswamy B; Cohn DE; Shapiro C; Andreassen PR; Otterson GA; Villalona-Calero MA
Transl Res; 2013 Mar; 161(3):156-64. PubMed ID: 23063585
[TBL] [Abstract][Full Text] [Related]
4. ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.
Bretz AC; Gittler MP; Charles JP; Gremke N; Eckhardt I; Mernberger M; Mandic R; Thomale J; Nist A; Wanzel M; Stiewe T
Nucleic Acids Res; 2016 Apr; 44(7):3204-18. PubMed ID: 26819410
[TBL] [Abstract][Full Text] [Related]
5. Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.
Chiappa M; Guffanti F; Grasselli C; Panini N; Corbelli A; Fiordaliso F; Damia G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474294
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
[TBL] [Abstract][Full Text] [Related]
7. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer.
Chen YF; Pang YC; Wang HC; Wu PE; Chen ZJ; Huang D; Peng DL; Yan YM; Liu C; Wu LC; Fan XZ; Cheng YX; Liu YQ
Br J Pharmacol; 2024 Apr; 181(8):1221-1237. PubMed ID: 37926864
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.
Mistry H; Hsieh G; Buhrlage SJ; Huang M; Park E; Cuny GD; Galinsky I; Stone RM; Gray NS; D'Andrea AD; Parmar K
Mol Cancer Ther; 2013 Dec; 12(12):2651-62. PubMed ID: 24130053
[TBL] [Abstract][Full Text] [Related]
9. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.
Huang F; Mazin AV
PLoS One; 2014; 9(6):e100993. PubMed ID: 24971740
[TBL] [Abstract][Full Text] [Related]
10. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells.
Tan Y; Li J; Zhao G; Huang KC; Cardenas H; Wang Y; Matei D; Cheng JX
Nat Commun; 2022 Aug; 13(1):4554. PubMed ID: 35931676
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p300 increases cytotoxicity of cisplatin in pancreatic cancer cells.
Bugbee T; Gathoni M; Payne C; Blubaugh M; Matlock K; Wixson T; Lu A; Stancic S; Chung PA; Palinski R; Wallace N
Gene; 2023 Dec; 888():147762. PubMed ID: 37666373
[TBL] [Abstract][Full Text] [Related]
12. Modeling injury and repair in kidney organoids reveals that homologous recombination governs tubular intrinsic repair.
Gupta N; Matsumoto T; Hiratsuka K; Garcia Saiz E; Galichon P; Miyoshi T; Susa K; Tatsumoto N; Yamashita M; Morizane R
Sci Transl Med; 2022 Mar; 14(634):eabj4772. PubMed ID: 35235339
[TBL] [Abstract][Full Text] [Related]
13. mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs.
David-West G; Ernlund A; Gadi A; Schneider RJ
Oncotarget; 2018 Sep; 9(69):33064-33076. PubMed ID: 30237852
[TBL] [Abstract][Full Text] [Related]
14. Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens.
Larsson P; Engqvist H; Biermann J; Werner Rönnerman E; Forssell-Aronsson E; Kovács A; Karlsson P; Helou K; Parris TZ
Sci Rep; 2020 Apr; 10(1):5798. PubMed ID: 32242081
[TBL] [Abstract][Full Text] [Related]
15. Fanconi anemia pathway regulation by FANCI in prostate cancer.
Kaljunen H; Taavitsainen S; Kaarijärvi R; Takala E; Paakinaho V; Nykter M; Bova GS; Ketola K
Front Oncol; 2023; 13():1260826. PubMed ID: 38023254
[TBL] [Abstract][Full Text] [Related]
16. Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells.
Verrelle P; Gestraud P; Poyer F; Soria A; Tessier S; Lescure A; Anthony E; Corbé M; Heinrich S; Beauvineau C; Chaput L; Granzhan A; Piguel S; Perez F; Teulade-Fichou MP; Megnin-Chanet F; Del Nery E
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1294-1307. PubMed ID: 37778425
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutation patterns and compound response in cancers.
He N; Kim N; Yoon S
BMB Rep; 2013 Feb; 46(2):97-102. PubMed ID: 23433112
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of potent And-1 inhibitors for cancer treatment.
Li J; Zhang Y; Sun J; Chen L; Gou W; Chen CW; Zhou Y; Li Z; Chan DW; Huang R; Pei H; Zheng W; Li Y; Xia M; Zhu W
Clin Transl Med; 2021 Dec; 11(12):e627. PubMed ID: 34923765
[TBL] [Abstract][Full Text] [Related]
19. Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents.
Wang Y; Nie G; Wang X; Ge W; Zhang Y
Bioorg Med Chem Lett; 2023 Nov; 96():129505. PubMed ID: 37838340
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response.
Zhu X; Wang X; Yan W; Yang H; Xiang Y; Lv F; Shi Y; Li HY; Lan L
NAR Cancer; 2021 Mar; 3(1):zcab010. PubMed ID: 33778494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
